Select region:

Clinical trials located in

Ancona

Ancona city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Ancona, located on Italy’s eastern coast, is a city steeped in history and rich in cultural heritage. Founded by Greek settlers in around 387 BC, its name derives from the Greek word “ankon,” meaning elbow, a reference to the city’s curved harbor. Ancona’s strategic position has made it a significant port throughout history, playing a pivotal role in trade and military campaigns. The city is home to the Arch of Trajan, a Roman architectural masterpiece built in 115 AD to honor Emperor Trajan. Additionally, Ancona’s Cathedral of San Ciriaco, perched atop Guasco Hill, showcases a blend of Romanesque and Byzantine styles, offering panoramic views of the Adriatic Sea. The city also endured heavy bombings during World War II, which adds to its historical complexity.

  • CT-EU-00054212

    Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    BelgiumFranceItalyPolandSpainUnited Kingdom
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    BelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandSpainUnited Kingdom
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    BelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomania
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    AustriaBelgiumFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Examining new treatment for digestive complications of Graft Versus Host Disease

    This study is examining the effects of a therapy called MaaT013 in patients who do not respond well to a drug called Ruxolitinib. Patients suffer from a disease called acute GVHD that affects their stomach. Previous studies have shown promising results, with most patients showing improvement after receiving MaaT013. Due to these results, MaaT013 will be used as “rescue therapy” in patients who do not improve with steroids or JAK inhibitors, drugs often used to treat the disease. The standard first treatment for acute GVHD is steroids, but some patients do not respond well to this treatment, and those who do may have serious side effects if they take high doses for a long time. Therefore, scientists are interested in exploring alternative treatments such as MaaT013. A drug called Ruxolitinib was approved by the FDA in 2019, but again, not all patients respond well to this treatment, prompting the need to develop alternatives.

    AustriaBelgiumFranceGermanyItalySpain
  • Sacituzumab trial for metastatic breast cancer patients

    This study is all about trying a medication named Sacituzumab Govitecan for individuals with a specific kind of breast cancer that has spread beyond the breast (metastatic) and is not affected by certain hormones or proteins. The goal is to see if this medicine can help people live longer by stopping the cancer from growing or spreading. This medicine will be compared with other usual treatments that your doctor may choose, such as paclitaxel or capecitabine. The study also aims to know the percentage of patients who see their cancer shrink as a result of the treatment. Furthermore, the study will also evaluate how the treatment impacts the overall well-being of the patients, through a series of questions related to physical, emotional, and social life.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyPolandPortugalSpainUnited Kingdom
  • CT-EU-00041228

    Long-term study of effects of gene-modified T cells therapy

    This study involves long-term tracking of patients who have undergone treatment with genetically modified (GM) T cells. This is a specialized approach in which T cells are changed in the laboratory. The primary goal is to evaluate the effectiveness and safety of this treatment. The study includes both children and adults who were treated with GMO T cells. To be eligible for the study, people must have undergone at least one GMO T-cell treatment. If the B cell test is negative after 5 years, continued annual follow-up will be carried out. This monitoring will continue until B cell counts return to normal at two subsequent assessments, for up to 15 years, or until the patient decides to withdraw from the study.

    AustriaBelgiumFinlandFranceGermanyItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • Testing birtamimab for safety and effectiveness in patients with severe AL Amyloidosis

    This medical study aims to investigate a drug called birtamimab to understand if it effectiveness and is safe for people in the advanced stage (Mayo Stage IV) of a disease called AL Amyloidosis. In this study, scientists are comparing the outcomes of two groups of people: one group receiving birtamimab in addition to standard-of-care chemotherapy, and another group receiving a neutral drug (placebo) along with standard-of-care chemotherapy. The goal is to assess whether the group receiving birtamimab has better results or outcomes compared to the group receiving the placebo. Around 150 patients with AL Amyloidosis will join the study. Patients will be chosen randomly to either receive birtamimab or placebo.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    AustriaBelgiumBulgariaDenmarkFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

    AustriaBelgiumFranceGermanyItalyNetherlandsPolandPortugalRomaniaSloveniaSpain
  • Testing new drug for lung fibrosis safety & effectiveness

    This study explores new treatment options for idiopathic pulmonary fibrosis (IPF) with a new drug called BMS-986278. The main goal is to thoroughly evaluate the effectiveness and safety of BMS-986278 in the treatment of IPF. During the study, participants will receive the drug under close supervision, allowing researchers to collect valuable data on its effects and potential benefits. This careful monitoring also ensures the safety and well-being of each participant. Participating in this study may provide insightful data on how IPF symptoms respond to this new treatment.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing the safety and effectiveness of a new drug in the treatment of pulmonary fibrosis

    This study is testing a new drug called BMS-986278 for a lung disease called progressive pulmonary fibrosis. This condition causes the lungs to become increasingly scarred over time, making breathing difficult. Randomly assigned participants will receive either the real drug or a fake drug (placebo) that doesn’t work. No one will know who gets what, not even doctors. The goal is to see if this new drug helps slow the progression of the disease, prevent patients from having to be hospitalized and/or increase their chances of survival. These outcomes will be measured by tracking breathing tests, any sudden, serious worsening of the disease, any hospital stays related to lung disease, and any deaths from any cause.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Advancing treatment options for Idiopathic Pulmonary Fibrosis

    This clinical trial examines the effectiveness of BMS-986278 in people with Idiopathic Pulmonary Fibrosis (IPF). Involving over 1,000 participants, the trial is designed to assess the drug’s efficacy, safety, and tolerability. Participants will receive either the study drug or a placebo. Key measures include changes in lung function, quality of life, and exercise capacity. This research could offer important insights for treating IPF, a condition that affects lung tissue.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom

See more clinical trials in other cities in Italy:

.